Revenue
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fate Therapeutics Inc (FATE)
Price$2.48Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M | $31.4M | $10.7M | $4.7M | $4.1M | $4.4M | $2.4M | — | $971,000 | $2.7M | $1.2M | — | — | — |
| Research & development | $107.8M | $135.0M | $172.6M | $320.5M | $215.5M | $125.6M | $87.8M | $56.0M | $34.4M | $26.5M | $19.9M | $16.4M | $12.0M | $12.0M | $9.9M | — | — | — |
| Operating expenses | $154.3M | $223.9M | $254.0M | $404.7M | $272.8M | $159.5M | $111.4M | $71.8M | $46.2M | $36.4M | $30.2M | $24.9M | $18.6M | $16.2M | $14.5M | — | — | — |
| Operating income | −$147.7M | −$210.3M | −$190.5M | −$308.4M | −$217.0M | −$128.1M | −$100.7M | −$67.1M | −$42.1M | −$32.0M | −$27.8M | −$24.9M | −$17.7M | −$13.6M | −$13.3M | — | — | — |
| Operating margin | −2,222.45% | −1,542.63% | −299.86% | −320.23% | −388.56% | −407.47% | −943.14% | −1,415.44% | −1,025.94% | −726.10% | −1,142.82% | — | −1,820.29% | −507.75% | −1,136.15% | — | — | — |
| EBITDA | −$134.8M | −$191.3M | −$172.2M | −$294.6M | −$211.1M | −$125.0M | −$98.5M | −$65.9M | −$41.2M | −$31.1M | −$27.1M | −$24.4M | −$17.1M | −$13.0M | −$12.6M | — | — | — |
| EBITDA margin | −2,028.33% | −1,403.52% | −271.09% | −305.95% | −378.08% | −397.65% | −922.60% | −1,390.04% | −1,002.29% | −706.09% | −1,114.56% | — | −1,761.48% | −485.66% | −1,078.72% | — | — | — |
| Net income | −$136.3M | −$186.3M | −$160.9M | −$281.7M | −$212.2M | −$173.4M | −$98.1M | −$66.6M | −$43.0M | −$33.5M | −$30.0M | −$25.9M | −$20.9M | −$14.2M | −$13.4M | −$16.2M | −$13.3M | −$7.2M |
| Net profit margin | −2,051.08% | −1,366.46% | −253.30% | −292.55% | −379.89% | −551.59% | −919.00% | −1,405.02% | −1,046.08% | −760.15% | −1,233.73% | — | −2,151.80% | −533.30% | −1,147.61% | — | — | — |
| Basic EPSper basic share | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 | -$2.10 | -$1.44 | -$1.19 | -$1.02 | -$1.05 | -$1.18 | -$1.27 | -$3.54 | -$13.06 | -$16.16 | — | — | — |
| Diluted EPSper diluted share | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 | -$2.10 | -$1.44 | -$1.19 | -$1.02 | -$1.05 | -$1.18 | -$1.27 | -$3.54 | -$13.06 | -$16.16 | — | — | — |
Owners
Reported shareholders
11.03%of listed shares
Redmile Group, LLC12.87M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Redmile Group, LLC | 11.03%12.87M shares |
RedCo II Master Fund, L.P. | ≈7.69%8.98M shares |
BlackRock, Inc. | 6.25%7.3M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.90%4.55M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.81%4.45M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.73%4.35M shares |
AQR CAPITAL MANAGEMENT LLC | 3.29%3.84M shares |
TWO SIGMA INVESTMENTS, LP | 3.08%3.59M shares |
JOHNSON & JOHNSON | 2.90%3.38M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.56%2.98M shares |
MILLENNIUM MANAGEMENT LLC | 2.09%2.43M shares |
GOLDMAN SACHS GROUP INC | 1.76%2.05M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.13%1.32M shares |
T. Rowe Price Investment Management, Inc. | 0.93%1.08M shares |
JANE STREET GROUP, LLC | 0.88%1.03M shares |
CITADEL ADVISORS LLC | 0.85%993.31K shares |
Bruce & Co., Inc. | 0.85%989.19K shares |
MORGAN STANLEY | 0.60%694.58K shares |
RASTETTER WILLIAM H | ≈0.55%642.42K shares |
VANGUARD FIDUCIARY TRUST CO | 0.55%640.43K shares |
Percentages use 116.69M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | TAHL CINDYSee Remarks | SellCommon Stock | 25.6K | $1.88 | $48.1K | 628.2K |
| May 20, 2026Form 4 | Valamehr BahramPresident and CEO | SellCommon Stock | 28.9K | $1.88 | $54.4K | 635.8K |
| Jan 9, 2026Form 4 | TAHL CINDYSee Remarks | SellCommon Stock | 10.6K | $1.06 | $11.2K | 387.1K |
| Jan 9, 2026Form 4 | Valamehr BahramPresident and CEO | SellCommon Stock | 5.2K | $1.07 | $5.6K | 329.7K |
| Aug 4, 2025Form 4 | TAHL CINDYSee Remarks | SellCommon Stock | 9.0K | $1.06 | $9.6K | 397.7K |
Community posts
Fate Therapeutics wins $15 million grant for lupus-nephritis trial
Fate Therapeutics ($FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support RECLAIM-LN, a Phase 2 study of FT819. The experimental off-the-shelf CAR-T treatment will be evaluated in approximatel ...
